Purpose To identify tissue microRNAs predictive of sunitinib activity in patients with
metastatic renal-cell-carcinoma (MRCC) and to evaluate in vitro their mechanism of action in …

To elucidate the impact of genetic variations in breast cancer resistance protein
(BCRP/ABCG2) and P-glycoprotein (MDR1/ABCB1) on the pharmacokinetics of sunitinib …

Background: There are no validated markers that predict response in metastatic renal cell
cancer (RCC) patients treated with sunitinib. We aim to study the impact of single-nucleotide …

Background Erlotinib shows large inter-patient pharmacokinetic variability, but the impact of
early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully …

Background Vascular endothelial growth factor (VEGF)-targeted therapy is the currently
standard treatment for advanced and metastatic renal cell carcinoma (RCC). Multiple …

Hypertension is an important side effect of sunitinib treatment. In a retrospective study in 255
patients, single‐nucleotide polymorphisms (SNPs) in vascular endothelial growth factor A …

Genomics is revolutionizing our understanding of the molecular basis of renal cell
carcinoma (RCC). The advent of unbiased genome-wide association studies has led to the …

Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …

Purpose Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a
randomized phase II trial comparing sunitinib treatment schedules, separate exploratory …

Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide
polymorphisms (SNPs) in PK candidate genes have been associated with the efficacy and …